{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:08Z","timestamp":1793159108482,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bioorg.2024.108109","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T02:28:58Z","timestamp":1735525738000},"page":"108109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel FGFR1 PROTACs"],"prefix":"10.1016","volume":"155","author":[{"given":"Yu-Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-3108","authenticated-orcid":false,"given":"Li-Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bioorg.2024.108109_b0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2024.108109_b0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2024.108109_b0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108109_b0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2024.108109_b0025","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res."},{"issue":"7417","key":"10.1016\/j.bioorg.2024.108109_b0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"The Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bioorg.2024.108109_b0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/path.2657","article-title":"Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype","volume":"220","author":"Murphy","year":"2010","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108109_b0040","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108109_b0045","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108109_b0050","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: from discovery to the clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2024.108109_b0055","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andr\u00e9","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108109_b0060","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor\u20051 (FGFR1) Irreversible Structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"issue":"8","key":"10.1016\/j.bioorg.2024.108109_b0065","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.108109_b0070","doi-asserted-by":"crossref","unstructured":"S. K. Pal, J. E. Rosenberg, J. H. Hoffman-Censits, R. Berger, D. I. Quinn, M. D. Galsky, J. Wolf, C. Dittrich, B. Keam, J.-P. Delord, J. H. M. Schellens, G. Gravis, J. Medioni, P. Maroto, V. Sriuranpong, C. Charoentum, H. A. Burris, V. Gr\u00fcnwald, D. Petrylak, U. Vaishampayan, E. Gez, U. De Giorgi, J.-L. Lee, J. Voortman, S. Gupta, S. Sharma, A. Mortazavi, D. J. Vaughn, R. Isaacs, K. Parker, X. Chen, K. Yu, D. Porter, D. Graus Porta, D. F. Bajorin, Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1\u20133 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma withFGFR3Alterations, Cancer Discov. 8 (7) (2018) 812-821. doi: 10.1158\/2159-8290.Cd-18-0229.","DOI":"10.1158\/2159-8290.CD-18-0229"},{"key":"10.1016\/j.bioorg.2024.108109_b0075","doi-asserted-by":"crossref","unstructured":"H. K. Koblish, L. Wu, L. S. Wang, P. C. C. Liu, R. Wynn, J. Rios-Doria, S. Spitz, H. Liu, A. Volgina, N. Zolotarjova, K. Kapilashrami, E. Behshad, M. Covington, Y. O. Yang, J. Li, S. Diamond, M. Soloviev, K. O'hayer, S. Rubin, C. Kanellopoulou, G. Yang, M. Rupar, D. Dimatteo, L. Lin, C. Stevens, Y. Zhang, P. Thekkat, R. Geschwindt, C. Marando, S. Yeleswaram, J. Jackson, P. Scherle, R. Huber, W. Yao, G. Hollis, Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor, Cancer Discov. 12 (6) (2022) 1482-1499. doi: 10.1158\/2159-8290.Cd-21-1156.","DOI":"10.1158\/2159-8290.CD-21-1156"},{"key":"10.1016\/j.bioorg.2024.108109_b0080","doi-asserted-by":"crossref","unstructured":"Y. Loriot, A. Necchi, S. H. Park, J. Garcia-Donas, R. Huddart, E. Burgess, M. Fleming, A. Rezazadeh, B. Mellado, S. Varlamov, M. Joshi, I. Duran, S. T. Tagawa, Y. Zakharia, B. Zhong, K. Stuyckens, A. Santiago-Walker, P. De Porre, A. O'hagan, A. Avadhani, A. O. Siefker-Radtke, Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma, N. Engl. J. Med. 381 (4) (2019) 338-348. doi: 10.1056\/NEJMoa1817323.","DOI":"10.1056\/NEJMoa1817323"},{"issue":"6","key":"10.1016\/j.bioorg.2024.108109_b0085","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Sch\u00f6nherr","year":"2024","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.bioorg.2024.108109_b0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bioorg.2024.108109_b0095","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/0008-5472.CAN-20-3555","article-title":"Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors","volume":"81","author":"Haga","year":"2021","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108109_b0100","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.bioorg.2024.108109_b0105","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108109_b0110","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41467-024-46006-3","article-title":"Deaggregation of mutant Plasmodium yoelii de-ubiquitinase UBP1 alters MDR1 localization to confer multidrug resistance","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108109_b0115","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.7150\/thno.92526","article-title":"Degraders in epigenetic therapy: PROTACs and beyond","volume":"14","author":"Dai","year":"2024","journal-title":"Theranostics."},{"issue":"18","key":"10.1016\/j.bioorg.2024.108109_b0120","doi-asserted-by":"crossref","first-page":"13028","DOI":"10.1021\/acs.jmedchem.3c00982","article-title":"Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108109_b0125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"issue":"29","key":"10.1016\/j.bioorg.2024.108109_b0130","doi-asserted-by":"crossref","first-page":"15905","DOI":"10.1002\/anie.202101328","article-title":"Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1\/2","volume":"60","author":"Du","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2024.108109_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128982","article-title":"Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform","volume":"75","author":"Guo","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108109_b0140","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108109_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116612","article-title":"Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor","volume":"275","author":"Hu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.108109_b0150","unstructured":"Etern biopharma shanghai co ltd. Pyrazole derivative for FGFR inhibitor and preparation method therefor. WO2021037219, (2021)."},{"key":"10.1016\/j.bioorg.2024.108109_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113645","article-title":"Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation","volume":"223","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2024.108109_b0160","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1021\/acs.jmedchem.1c00996","article-title":"Proteolysis-Targeting Chimera (PROTAC) modification of Dovitinib enhances the antiproliferative effect against FLT3-ITD-Positive acute myeloid Leukemia cells","volume":"64","author":"Cao","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.108109_b0165","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.bmcl.2016.04.028","article-title":"Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors","volume":"26","author":"Fan","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.108109_b0170","doi-asserted-by":"crossref","unstructured":"Y. M. Han Wang, Lehao Bu, Wenxin Chen, Lei Gao, Cong Sun, New and convergent synthesis of AZD4547, Heterocycles. 100 (2020) 276-282. doi: 10.3987\/COM-20-14215.","DOI":"10.3987\/COM-20-14215"},{"key":"10.1016\/j.bioorg.2024.108109_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112990","article-title":"Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3)","volume":"210","author":"Yamani","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"7512","key":"10.1016\/j.bioorg.2024.108109_b0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bioorg.2024.108109_b0185","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.bmc.2016.03.036","article-title":"Design, synthesis and biological evaluation of 5-amino-4-(1H-benzoimidazol-2-yl)-phenyl-1,2-dihydro-pyrrol-3-ones as inhibitors of protein kinase FGFR1","volume":"24","author":"Gryshchenko","year":"2016","journal-title":"Biorg. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824010149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824010149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T16:10:25Z","timestamp":1740327025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824010149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"alternative-id":["S0045206824010149"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108109","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel FGFR1 PROTACs","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108109"}}